Krystal Biotech (NASDAQ: KRYS) reported quarterly earnings of $1.70 per share which beat the analyst consensus estimate of $1.39 by 22.21 percent. This is a 11.84 percent increase over earnings of $1.52 per share from the same period last year. The company reported quarterly sales of $107.105 million which beat the analyst consensus estimate of $105.338 million by 1.68 percent. This is a 17.52 percent increase over sales of $91.139 million the same period last year.